Pub Date : 2016-05-03DOI: 10.1080/23809000.2016.1181976
Mellar P. Davis, Cheryl M Carrino
ABSTRACT Palliative care has changed since its inception with Dr Balfour Mount in 1976. It is moving slowly from the care of the dying (which is still an important part of palliative care) and crisis intervention to integrated care with oncology early in the course of advanced cancer. Several studies have demonstrated the advantages to this approach. In this review we will discuss indicators of structure process and outcomes, outcomes to integration, components to successful integration of care and barriers to integrated care. Family financial toxicity related to cancer care is a growing problem that will need to be measured as an outcome to integrated care
{"title":"Promoting further use of palliative care in cancer care centers","authors":"Mellar P. Davis, Cheryl M Carrino","doi":"10.1080/23809000.2016.1181976","DOIUrl":"https://doi.org/10.1080/23809000.2016.1181976","url":null,"abstract":"ABSTRACT Palliative care has changed since its inception with Dr Balfour Mount in 1976. It is moving slowly from the care of the dying (which is still an important part of palliative care) and crisis intervention to integrated care with oncology early in the course of advanced cancer. Several studies have demonstrated the advantages to this approach. In this review we will discuss indicators of structure process and outcomes, outcomes to integration, components to successful integration of care and barriers to integrated care. Family financial toxicity related to cancer care is a growing problem that will need to be measured as an outcome to integrated care","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"14 1","pages":"213 - 220"},"PeriodicalIF":0.0,"publicationDate":"2016-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1181976","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-03DOI: 10.1080/23809000.2016.1191318
Ashley L Artese, Emily Simonavice, L. Panton
ABSTRACT While prognosis for breast cancer has improved, breast cancer survivors (BCS) contend with numerous side effects from cancer treatment. One side effect is an accelerated loss of bone mineral density (BMD) of 2-8% during treatment. While pharmacological treatments may be effective in combatting BMD loss, these medications may cause unwanted side effects. Resistance training may serve as an effective alternative to pharmacological treatments to help preserve BMD. The current literature shows that resistance training has been successful in maintaining BMD among BCS compared to non-exercising controls both during and after cancer treatments. While this non-pharmacological method may be helpful in attenuating BMD losses, there is no evidence supporting resistance training as a sufficient method for increasing BMD in BCS. Therefore, more research is needed to determine if resistance training alone or combined with higher impact exercises (plyometrics, hopping, jumping) has the potential to elicit BMD improvements in BCS.
{"title":"The benefits of resistance training in breast cancer survivors: a focus on maintaining bone density","authors":"Ashley L Artese, Emily Simonavice, L. Panton","doi":"10.1080/23809000.2016.1191318","DOIUrl":"https://doi.org/10.1080/23809000.2016.1191318","url":null,"abstract":"ABSTRACT While prognosis for breast cancer has improved, breast cancer survivors (BCS) contend with numerous side effects from cancer treatment. One side effect is an accelerated loss of bone mineral density (BMD) of 2-8% during treatment. While pharmacological treatments may be effective in combatting BMD loss, these medications may cause unwanted side effects. Resistance training may serve as an effective alternative to pharmacological treatments to help preserve BMD. The current literature shows that resistance training has been successful in maintaining BMD among BCS compared to non-exercising controls both during and after cancer treatments. While this non-pharmacological method may be helpful in attenuating BMD losses, there is no evidence supporting resistance training as a sufficient method for increasing BMD in BCS. Therefore, more research is needed to determine if resistance training alone or combined with higher impact exercises (plyometrics, hopping, jumping) has the potential to elicit BMD improvements in BCS.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"239 - 248"},"PeriodicalIF":0.0,"publicationDate":"2016-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1191318","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-03DOI: 10.1080/23809000.2016.1181977
A. Chan, Terence Ng, R. Chan, E. Poon, M. Farid
An adolescent and young adult (AYA) cancer patient is defined as an individual of 15 to 39 years of age at the time of initial cancer diagnosis.1,2 The number of AYA cancer survivors has dramatically increased over the past decades due to availability of novel therapeutics, with the 5-year overall survival rate among adolescents aged 15 to 19 years old exceeds 80% for most cancers.3 AYA cancer survivors, however, often experience a myriad of treatment-related chronic and late toxicities that can lead to functional impairment at great economic, emotional and social cost.4 As the cure rates of AYA cancers continue to improve and survivors live longer, post-treatment health issues in these survivors are becoming increasingly relevant, and more in-depth research is needed in this group of patients...
{"title":"Are adolescent and young adult cancer patients affected by ‘chemobrain’?: a call for evidence","authors":"A. Chan, Terence Ng, R. Chan, E. Poon, M. Farid","doi":"10.1080/23809000.2016.1181977","DOIUrl":"https://doi.org/10.1080/23809000.2016.1181977","url":null,"abstract":"An adolescent and young adult (AYA) cancer patient is defined as an individual of 15 to 39 years of age at the time of initial cancer diagnosis.1,2 The number of AYA cancer survivors has dramatically increased over the past decades due to availability of novel therapeutics, with the 5-year overall survival rate among adolescents aged 15 to 19 years old exceeds 80% for most cancers.3 AYA cancer survivors, however, often experience a myriad of treatment-related chronic and late toxicities that can lead to functional impairment at great economic, emotional and social cost.4 As the cure rates of AYA cancers continue to improve and survivors live longer, post-treatment health issues in these survivors are becoming increasingly relevant, and more in-depth research is needed in this group of patients...","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"187 - 188"},"PeriodicalIF":0.0,"publicationDate":"2016-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1181977","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-03DOI: 10.1080/23809000.2016.1185368
A. Smits, A. Lopes, R. Bekkers, L. Massuger, K. Galaal
ABSTRACT Endometrial cancer and ovarian cancer are the most common gynaecological cancers in the developed world and are known to be associated with obesity. The escalating obesity epidemic in countries such as the United Kingdom has resulted in the majority of these patients being overweight or obese. Despite studies reporting on adverse effects of obesity throughout endometrial and ovarian cancer treatment and survivorship, a comprehensive overview is still unavailable. Given the fact gynaecological oncologists increasingly treat women within the obese, morbidly obese and even super obese classifications, it is essential to develop appropriate guidelines for clinical care. Through an analysis of the existing literature, we present a review of the current knowledge of the effect of body mass index on outcomes of endometrial and ovarian cancer patients, including treatment outcomes, quality of life and survival.
{"title":"Body mass index and outcomes of endometrial and ovarian cancer patients","authors":"A. Smits, A. Lopes, R. Bekkers, L. Massuger, K. Galaal","doi":"10.1080/23809000.2016.1185368","DOIUrl":"https://doi.org/10.1080/23809000.2016.1185368","url":null,"abstract":"ABSTRACT Endometrial cancer and ovarian cancer are the most common gynaecological cancers in the developed world and are known to be associated with obesity. The escalating obesity epidemic in countries such as the United Kingdom has resulted in the majority of these patients being overweight or obese. Despite studies reporting on adverse effects of obesity throughout endometrial and ovarian cancer treatment and survivorship, a comprehensive overview is still unavailable. Given the fact gynaecological oncologists increasingly treat women within the obese, morbidly obese and even super obese classifications, it is essential to develop appropriate guidelines for clinical care. Through an analysis of the existing literature, we present a review of the current knowledge of the effect of body mass index on outcomes of endometrial and ovarian cancer patients, including treatment outcomes, quality of life and survival.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"221 - 229"},"PeriodicalIF":0.0,"publicationDate":"2016-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1185368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-03DOI: 10.1080/23809000.2016.1181975
Jennifer Thomas, Utsav K. Radia, J. Ramsay, C. Jayasena
ABSTRACT Steady improvements in the long term outlook for adolescents and young adults with cancer require a shift in focus towards ensuring quality of life after cancer treatment as well as quantity. An important component of quality of life for many men is the ability to father a biological child. However, direct effects of malignancy, as well as potentially gonadotoxic cancer treatments, render many men azoospermic. Where cryopreservation of a good quality semen sample is not possible or was not offered prior to initiation of treatment, microdissection testicular sperm extraction (mTESE) offers a potential route to biological fatherhood. This review explores current evidence supporting the use of mTESE in patients treated for cancer, as well as some of the barriers and questions that still remain before this technique can form part of routine practice.
{"title":"Microdissection testicular sperm extraction for men undergoing cancer treatment","authors":"Jennifer Thomas, Utsav K. Radia, J. Ramsay, C. Jayasena","doi":"10.1080/23809000.2016.1181975","DOIUrl":"https://doi.org/10.1080/23809000.2016.1181975","url":null,"abstract":"ABSTRACT Steady improvements in the long term outlook for adolescents and young adults with cancer require a shift in focus towards ensuring quality of life after cancer treatment as well as quantity. An important component of quality of life for many men is the ability to father a biological child. However, direct effects of malignancy, as well as potentially gonadotoxic cancer treatments, render many men azoospermic. Where cryopreservation of a good quality semen sample is not possible or was not offered prior to initiation of treatment, microdissection testicular sperm extraction (mTESE) offers a potential route to biological fatherhood. This review explores current evidence supporting the use of mTESE in patients treated for cancer, as well as some of the barriers and questions that still remain before this technique can form part of routine practice.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"207 - 212"},"PeriodicalIF":0.0,"publicationDate":"2016-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1181975","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-03DOI: 10.1080/23809000.2016.1184089
I. Zapico, Laura Cabiedes, T. Iglesias
ABSTRACT Introduction: Most new antineoplastic agents (NAAs) must undergo a complex and subject-to-uncertainty selection process before they are included in Hospital Formularies. The aim of this study is to quantify the temporal differences for NAA inclusion across Spanish hospitals and to identify the potential predictive factors for actual access times. Methods: A panel of NAAs approved by the Spanish Drug and Sanitary Products Agency from 2000 to 2010 was studied. A Cox regression model was performed in order to detect the potential predictors of time to NAA inclusion across hospitals. Results: Disparities in time to NAA access were identified. Several factors were found to be associated with faster access, the most important hospital participation in clinical trials. Orphan product designation, among others, was related to delayed access.
{"title":"Patient access to new oncology medicines in the Spanish hospital setting: exploring explanatory factors through a Cox regression model","authors":"I. Zapico, Laura Cabiedes, T. Iglesias","doi":"10.1080/23809000.2016.1184089","DOIUrl":"https://doi.org/10.1080/23809000.2016.1184089","url":null,"abstract":"ABSTRACT Introduction: Most new antineoplastic agents (NAAs) must undergo a complex and subject-to-uncertainty selection process before they are included in Hospital Formularies. The aim of this study is to quantify the temporal differences for NAA inclusion across Spanish hospitals and to identify the potential predictive factors for actual access times. Methods: A panel of NAAs approved by the Spanish Drug and Sanitary Products Agency from 2000 to 2010 was studied. A Cox regression model was performed in order to detect the potential predictors of time to NAA inclusion across hospitals. Results: Disparities in time to NAA access were identified. Several factors were found to be associated with faster access, the most important hospital participation in clinical trials. Orphan product designation, among others, was related to delayed access.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"249 - 255"},"PeriodicalIF":0.0,"publicationDate":"2016-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1184089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-18DOI: 10.1080/23809000.2016.1174068
Y. Hao, Meaghan Krohe, I. Mazar, N. Galipeau, C. Foley, D. Globe, D. Turner-Bowker, A. Shields
ABSTRACT Patient-reported outcome (PRO) measures are used in clinical research and practice for the assessment of disease-related symptoms and impacts as well as treatment-related side effects, from the patient perspective. However, a systematic examination of the role of PROs in metastatic breast cancer treatment approvals is lacking. A review of FDA labels and historical drug approval documents for metastatic breast cancer treatments was conducted to determine how PROs had been used or pursued to support labeling claims. In the historical drug approval documents, PROs were often being implemented by sponsors, and regulatory reviewers noted several issues limiting their suitability to support label claims. The findings suggest there is much room for improvement in how sponsors develop, implement, and report PRO measurement strategies as part of drug approval.
{"title":"Patient-reported outcomes in advanced breast cancer: inside the label and approval documents","authors":"Y. Hao, Meaghan Krohe, I. Mazar, N. Galipeau, C. Foley, D. Globe, D. Turner-Bowker, A. Shields","doi":"10.1080/23809000.2016.1174068","DOIUrl":"https://doi.org/10.1080/23809000.2016.1174068","url":null,"abstract":"ABSTRACT Patient-reported outcome (PRO) measures are used in clinical research and practice for the assessment of disease-related symptoms and impacts as well as treatment-related side effects, from the patient perspective. However, a systematic examination of the role of PROs in metastatic breast cancer treatment approvals is lacking. A review of FDA labels and historical drug approval documents for metastatic breast cancer treatments was conducted to determine how PROs had been used or pursued to support labeling claims. In the historical drug approval documents, PROs were often being implemented by sponsors, and regulatory reviewers noted several issues limiting their suitability to support label claims. The findings suggest there is much room for improvement in how sponsors develop, implement, and report PRO measurement strategies as part of drug approval.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"197 - 205"},"PeriodicalIF":0.0,"publicationDate":"2016-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1174068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-18DOI: 10.1080/23809000.2016.1174069
A. Batra, S. Bakhshi
ABSTRACT Chemotherapy induced nausea and vomiting is the one of the most dreaded complication of chemotherapy in pediatric and adult cancers. Aprepitant is a neurokinin-1 antagonist that has shown significant efficacy in controlling acute and delayed chemotherapy induced nausea and vomiting when added to the backbone of type 3 serotonin 5- hydroxytryptamine receptor antagonist and corticosteroid in patients receiving moderately and highly emetogenic chemotherapy. There is abundant data in adults regarding the use aprepitant as an anti-emetic prophylactic agent; the data in pediatric patients are limited. However, increasing number of studies is being reported in pediatric cancer patients. Two phase 3 trials have been reported in last year that showed significant efficacy of aprepitant in pediatric population in decreasing the incidence and severity of chemotherapy induced nausea and vomiting. We hereby present the consolidated existing data regarding the safety and efficacy of aprepitant in pediatric cancer patients.
{"title":"The safety and efficacy of aprepitant in combination with other antiemetic agents for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric patients","authors":"A. Batra, S. Bakhshi","doi":"10.1080/23809000.2016.1174069","DOIUrl":"https://doi.org/10.1080/23809000.2016.1174069","url":null,"abstract":"ABSTRACT Chemotherapy induced nausea and vomiting is the one of the most dreaded complication of chemotherapy in pediatric and adult cancers. Aprepitant is a neurokinin-1 antagonist that has shown significant efficacy in controlling acute and delayed chemotherapy induced nausea and vomiting when added to the backbone of type 3 serotonin 5- hydroxytryptamine receptor antagonist and corticosteroid in patients receiving moderately and highly emetogenic chemotherapy. There is abundant data in adults regarding the use aprepitant as an anti-emetic prophylactic agent; the data in pediatric patients are limited. However, increasing number of studies is being reported in pediatric cancer patients. Two phase 3 trials have been reported in last year that showed significant efficacy of aprepitant in pediatric population in decreasing the incidence and severity of chemotherapy induced nausea and vomiting. We hereby present the consolidated existing data regarding the safety and efficacy of aprepitant in pediatric cancer patients.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"189 - 195"},"PeriodicalIF":0.0,"publicationDate":"2016-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1174069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-03DOI: 10.1080/23809000.2016.1161491
M. De Vos
ABSTRACT Immature oocytes are an emerging source of gametes in patients with a diagnosis of cancer who have not enough time to undergo stimulation of their ovaries to obtain mature oocytes for fertility preservation. Immature oocytes can be harvested transvaginally from small antral follicles without hormonal pretreatment, mature in vitro and cryopreserved for future use. Oocytes can also be retrieved from extracorporeal ovarian tissue. After in vitro maturation (IVM), these oocytes can be fertilised and result in live births. The combination of fertility preservation methods may raise the hope of delayed childbearing to an increasing population of young cancer patients who undergo gonadotoxic cancer treatment. The lessons learnt from IVM in animal research and in the fertility clinic should soon transpire into improved efficiency of this approach in the context of oncofertility.
{"title":"Fertility preservation in women with cancer: in vitro maturation of oocytes","authors":"M. De Vos","doi":"10.1080/23809000.2016.1161491","DOIUrl":"https://doi.org/10.1080/23809000.2016.1161491","url":null,"abstract":"ABSTRACT Immature oocytes are an emerging source of gametes in patients with a diagnosis of cancer who have not enough time to undergo stimulation of their ovaries to obtain mature oocytes for fertility preservation. Immature oocytes can be harvested transvaginally from small antral follicles without hormonal pretreatment, mature in vitro and cryopreserved for future use. Oocytes can also be retrieved from extracorporeal ovarian tissue. After in vitro maturation (IVM), these oocytes can be fertilised and result in live births. The combination of fertility preservation methods may raise the hope of delayed childbearing to an increasing population of young cancer patients who undergo gonadotoxic cancer treatment. The lessons learnt from IVM in animal research and in the fertility clinic should soon transpire into improved efficiency of this approach in the context of oncofertility.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"127 - 135"},"PeriodicalIF":0.0,"publicationDate":"2016-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1161491","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-03DOI: 10.1080/23809000.2016.1157002
E. Mioranza, C. Falci, M. Dieci, V. Guarneri, P. Conte
ABSTRACT Although endocrine therapy (ET) plays a crucial role in the adjuvant treatment of ER-positive breast cancer, a significant proportion of patients discontinue treatment early because of toxicity. In recent years a number of papers have attempted to quantify the impact of adjuvant ET on the quality-of-life (QOL) of the patient. The aim of this present review is to report the results of prospective trials that have measured the effect of adjuvant ET on the QOL in breast cancer patients. In most trials a great discrepancy has emerged between the magnitude of treatment-related symptoms and a drop in different QOL domains. In fact, the average change of QOL scores, if present, was unexpectedly small. Moreover, aromatase inhibitors were shown to have an unfavorable profile when compared to tamoxifen, in the up-front or switched schedule, or to placebo, in the extended strategy. Further studies are warranted to implement more sensitive and largely accepted QOL instruments.
{"title":"The impact of adjuvant endocrine therapy in early breast cancer on quality-of-life: an overview of prospective trials","authors":"E. Mioranza, C. Falci, M. Dieci, V. Guarneri, P. Conte","doi":"10.1080/23809000.2016.1157002","DOIUrl":"https://doi.org/10.1080/23809000.2016.1157002","url":null,"abstract":"ABSTRACT Although endocrine therapy (ET) plays a crucial role in the adjuvant treatment of ER-positive breast cancer, a significant proportion of patients discontinue treatment early because of toxicity. In recent years a number of papers have attempted to quantify the impact of adjuvant ET on the quality-of-life (QOL) of the patient. The aim of this present review is to report the results of prospective trials that have measured the effect of adjuvant ET on the QOL in breast cancer patients. In most trials a great discrepancy has emerged between the magnitude of treatment-related symptoms and a drop in different QOL domains. In fact, the average change of QOL scores, if present, was unexpectedly small. Moreover, aromatase inhibitors were shown to have an unfavorable profile when compared to tamoxifen, in the up-front or switched schedule, or to placebo, in the extended strategy. Further studies are warranted to implement more sensitive and largely accepted QOL instruments.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"111 - 120"},"PeriodicalIF":0.0,"publicationDate":"2016-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1157002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：